EN
CN JPN
Healthcare & Life Science
    • Back

    Grandall has been deeply involved in the medical, healthcare, and life sciences industries with the aim of using professional legal services to continuously improve sustainable industry development. Most of Grandall's lawyers in this practice area have backgrounds working with pharmaceutical companies and years of industry experience, with some even having backgrounds in medicine or forensic medicine and experience as clinical practitioners, successfully resolving different legal issues during their work for clients in the medical, pharmaceutical and life science sectors.

    2. Draft and Review of Compliance System
    4. Draft and review of internal corporate system related to product sales promotion, drug research and development experiments, and third-party management, compliance training for executives and employees, supervision of the implementation of compliance system, and review and analysis of commercial mode compliance and consulting services for medical and health institutions
    7. Anti-Commercial Bribery and Response to Internal and External Investigations
    9. Response to law enforcement by industrial and commerce administrative authorities and other government departments, and company internal investigations, assisting foreign clients in responding to compliance investigations on corruption and bribery conducted by overseas regulatory bodies on their Chinese institutions
    12. Regulatory Compliance
    14. Legal consultation and services related to the regulation of pharmaceutical/medical device products, such as clinical trials, product registration, GMP compliance, product promotion, product recall, bidding, anti-monopoly and price control, etc.; comprehensive legal regulatory consulting services for medical and health institutions, including access, medical insurance, pricing, items, quality control, and health supervision
    17. Restructuring and Reorganization
    19. Restructuring, conversion and reorganization of property rights, interests, and operation rights for state-owned enterprises, non-profit organizations
    22. Dispute Resolution
    24. Dealing with disputes related to pharmaceutical and medical device products, such as disputes arising from various service contracts, distribution agreements, drug clinical trials, medical damage compensation, monopoly and unfair competition, etc.
    27. Investment, Financing and M&A
    29. Equity/property rights/interests investment, financing and M&A for enterprises, non-enterprises entities in the medical and healthcare industry
    32. Private Equity and Venture Capital
    34. Establishment, fundraising, liquidation, dissolution, and routine management of private equity/venture capital funds invested in the healthcare and life sciences industries, as well as the entire process from investment, M&A to exit
    37. Intellectual Property
    39. Drug research and development, patent strategy, technology transfer, cooperation, development, licensing, and dispute resolution for intellectual property

    Jinhushen Biopharma's acquisition of Tianjin Pharmaceutical - The largest M&A deal in Chinese pharmaceutical industry in the past five years, Deal of the Year 2021 by China Business Law Journal

    Nanjing Cenbest's acquisition of DENDREON pharmaceuticals project - the largest acquisition by a Chinese listed company in U.S. pharmaceutical industry, Deal of the Year 2018 by China Business Law Journal

    Pingan Health's listing on HKEx - Deal of the Year 2018 by Asian Mena Counsel, Deal of the Year 2018 by China Business Law Journal

    First IPO in the FMDV vaccine industry: Shen Lian Biomedical

    First IPO in the genetics industry: BGI Genomics

    First STAR listing of an A+H listed pharmaceutical company: Haohai Biotechnology

    HKEx listing for Fosun Pharma's subsidiary - Sisram Medical Ltd. - one of the few big overseas listing projects under red chip model

    Phase I asset-backed special plan of marketing accounts receivable for Guoxin-Taslypharma - innovatively designed the differential payment guarantee with a condition for release clause, being the first debt financing product issued in China

    Acquisition syndicate project for Esaote Group

    West China Dental's acquisition of a HK listed company

    China Resources Land's acquisition of medical care project of Nanjing Weiyuanzhou Co., Ltd.

    Huatai ZiJin's new round of billion yuan financing for Yikelai Biopharmaceuticals

    Debt restructuring project of Ningbo Fifth Hospital

    Government investment attraction cooperation project for Jiulongpo District Public Hospital

    KOHOEN's strategic cooperation with Chinese enterprises in the field of elderly care

    Acebright Pharma's project of the first generic launch of "Neratinib"

    ...